Finotonlimab is a humanized IgG4κ monoclonal antibody that targets programmed cell death protein 1 (PD-1/CD279), an immune checkpoint receptor involved in regulation of T-cell activity. Finotonlimab is also identified by the development code SCT-I10A.
Finotonlimab has a reported molecular weight of approximately 145.38 kDa and is classified as a monoclonal antibody rather than a conventional small-molecule active pharmaceutical ingredient.
Finotonlimab binds to the PD-1 receptor and blocks interaction between PD-1 and its ligands PD-L1 and PD-L2. This can enhance T-cell activity and contribute to antitumor immune responses. Preclinical research reported high-affinity binding to human PD-1 and inhibition of PD-1/PD-L1 and PD-1/PD-L2 interactions.
Finotonlimab has been investigated and developed as an anti-PD-1 immunotherapy for solid tumors. Published clinical research has evaluated finotonlimab in recurrent or metastatic head and neck squamous cell carcinoma and other solid-tumor settings.
The International Nonproprietary Name record classifies finotonlimab as an immunomodulator and antineoplastic monoclonal antibody.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Water Content | NMT 0.5% |